EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of Intravitreal Dexamethasone Implant in Treatment-Resistant Diabetic Macular Edema: Six-month Results

Mustafa Berhuni, İbrahim Edhem Yılmaz, Gürbostan Soysal Gizem, Zeynep Özer Özcan, Levent Doğan

Czech and Slovak Ophthalmology · 2025

DOI: 10.31348/2025/4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Czech and Slovak Ophthalmology, 2025. Verfasst von Mustafa Berhuni und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Macular Edema, Dexamethasone, Diabetic Retinopathy, Glucocorticoids. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To investigate the efficacy and safety of intravitreal Dexamethasone implant (DEX-I) therapy in the treatment of diabetic macular edema (DME) refractory to intravitreal bevacizumab (IVB). Material and methods: This retrospective and cross-sectional study included 37 eyes of 37 patients who received 3 loading doses of IVB injections for DME with no response and underwent DEX-I implant. Best-corrected visual acuity (BCVA), intraocular pressure (IOP) measurements and central foveal thickness (CFT) measured by spectral domain optical coherence tomography (SD-OCT) were recorded and compared before DEX-I, at the first week, first, second, third and sixth months. Duration of DME, glycated hemoglobin (HbA1c) levels, DME types and lens status (phakic, pseudophakic) were also recorded.

Results

The mean age of the patients was 61.14 ±8.69 years (59.5% male, 40.5% female). 35.1% of the patients had cystoid macular edema, 64.9% had diffuse macular edema and 73 % were phakic and 27% were pseudophakic. BCVA, CFT and IOP values before DEX-I injection were 0.78 ±0.16 LogMAR, 493.73 ±107.6 µm and 13.05 ±2.59 mmHg, respectively. At 6 months after DEX-I, BCVA, CFT and IOP values were 0.64 ±0.11 LogMAR, 397.35 ±59.72 µm and 16.3 ±2.51 mmHg, respectively. In all follow-ups, there was a significant improvement in BCVA, a significant decrease in CFT and a significant increase in IOP compared to pre-injection. Ocular hypertension was observed in 0.8 % of patients and progression of cataract progression in 1% of patients after treatment.

Conclusion

DEX-I therapy is an effective and safe treatment option for DME refractory to IVB treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Macular EdemaDexamethasoneDiabetic RetinopathyGlucocorticoidsHumansMaleFemaleMiddle AgedIntravitreal InjectionsDrug ImplantsAgedRetrospective StudiesVisual AcuityTomography, Optical CoherenceCross-Sectional Studies

Stichwörter der Autor:innen

Dexamethasone implantbevacizumabcataractdiabetic macular edemaintraocular pressure

Substanzen

DexamethasoneDrug ImplantsGlucocorticoids

Zitieren

APA

Berhuni, M., Yılmaz, İ. E., Gizem, G. S., Özcan, Z. Ö., & Doğan, L. (2025). Efficacy and Safety of Intravitreal Dexamethasone Implant in Treatment-Resistant Diabetic Macular Edema: Six-month Results. Czech and Slovak Ophthalmology. https://doi.org/10.31348/2025/4

Vancouver

Berhuni M, Yılmaz İE, Gizem GS, Özcan ZÖ, Doğan L. Efficacy and Safety of Intravitreal Dexamethasone Implant in Treatment-Resistant Diabetic Macular Edema: Six-month Results. Czech and Slovak Ophthalmology. 2025. doi:10.31348/2025/4

BibTeX
@article{Berhuni2025,
  author = {Berhuni, Mustafa and Yılmaz, İbrahim Edhem and Gizem, Gürbostan Soysal and Özcan, Zeynep Özer and Doğan, Levent},
  title = {Efficacy and Safety of Intravitreal Dexamethasone Implant in Treatment-Resistant Diabetic Macular Edema: Six-month Results},
  journal = {Czech and Slovak Ophthalmology},
  year = {2025},
  doi = {10.31348/2025/4}
}
Kostenlos starten →